COO Andrew Alasdair Buys 200,000 Zero‑Cost Options as MEDICUS Pharma Eyes Breakthrough SkinJect Trial Results
COO Andrew Alasdair’s 200k zero‑strike stock‑option grant signals confidence in MEDICUS Pharma’s SkinJect trial, hinting at future upside for investors.
4 minutes to read